Novel anti-fibrotic engineered macrophage therapy reduced liver fibrosis in preclinical models Development candidate nomination expected in the first quarter of 2025 PHILADELPHIA, May 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new data demonstrating preclinical proof of concept using engineered anti-fibrotic macrophages for the treat ...

Industry veteran with expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development PHILADELPHIA, May 2, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S. as the Company's Chief Medical Officer. Dr. Kennedy brings over 15 years of cli ...

PHILADELPHIA, April 24, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting taking place from May 31- June 4, 2024, in Chicago, IL. Details on the poster presentation at ASCO 2024 are below: Poster Title: A phase 1, first-in-human study of autologou ...

Shares of Carisma Therapeutics Inc. (CARM) have been struggling lately and have lost 12.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-K ____________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________to _________________ Com ...

现金及现金等价物情况 - Carisma Therapeutics Inc. 2023年第四季度和全年12月31日的现金及现金等价物为7760万美元[16] - Carisma Therapeutics Inc. 2023年12月的现金及现金等价物为77605千美元，较2022年增长219.7%[27] 研发费用 - 研发费用在2023年第四季度和全年12月31日分别为1940万美元和7410万美元，较去年同期增加了1750万美元[16] - Carisma Therapeutics Inc. 2023年研发支出为19415千美元，较2022年增长7.4%[28] 财务展望 - 总体而言，Carisma预计其截至2023年12月31日的现金及现金等价物为7760万美元，加上实施修订后的运营计划预期的成本节约，足以支持其计划的运营至2025年第三季度[19] 合作收入 - Carisma Therapeutics Inc. 2023年12月的合作收入为4289千美元，较2022年同期增长14.9%[28]

公司项目 - 公司决定将CT-0525作为其抗HER2 CAR-M产品候选者，并停止进一步开发CT-0508[1] - 公司的其他重点项目包括与Moderna的体内CAR-M合作以及包括纤维化在内的研究项目[1] - 公司决定优先发展CT-0525作为其抗HER2项目中的开发候选者，因为CAR-Monocyte相比CAR-Macrophage具有约2000倍的总暴露增加[4] 资金情况 - 公司截至2023年12月31日的现金及现金等价物为7760万美元，结合对运营的重组，包括暂停CT-1119的开发，预计资金将支持公司至2025年第三季度[1] - 公司预计其截至2023年12月31日的现金及现金等价物7760万美元，结合实施修订后的运营计划的预期成本节约，足以支持其计划的运营至2025年第三季度[20] 研究进展 - CT-0525在2023年11月获得美国食品和药物管理局（FDA）批准其新药申请（IND）的清关[5] - 公司预计将于2024年第二季度治疗CT-0525第一名患者，并计划在2024年年底报告该研究的初步数据[6] - 公司计划继续对参与Study 101的受试者进行所有研究操作，但计划停止招募新患者，并预计在2024年第二季度报告评估CT-0508和pembrolizumab联合使用的研究数据[9] 公司运营 - 公司决定暂停CT-1119的进一步开发，作为其重新优先考虑计划的一部分，待额外融资[10] - 公司预计将在2024年第二季度裁减约37%的员工[14] 财务数据 - Carisma Therapeutics Inc.在2023年的总资产为$89,554，较上一年的$72,153有所增长[29] - Carisma Therapeutics Inc.在2023年的合作收入为$14,919，较上一年的$9,834有所增长[29] - Carisma Therapeutics Inc.在2023年的研发支出为$74,125，较上一年的$56,618有所增长[29] - Carisma Therapeutics Inc.在2023年的每股普通股基本和稀释净亏损分别为$2.59和$28.77[30]

Carisma Therapeutics Inc.任命John Hohneker, M.D.为董事会成员 - Carisma Therapeutics Inc.宣布任命John Hohneker, M.D.为公司董事会成员[1] - Chidozie Ugwumba因其他职业承诺辞去Carisma董事会成员和审计委员会主席职务[1] John Hohneker, M.D.的丰富经验 - John Hohneker, M.D.在生物制药领域拥有超过30年的丰富经验[2] Carisma Therapeutics Inc.的业务重点 - Carisma Therapeutics Inc.是一家专注于开发创新免疫疗法的临床阶段生物制药公司[4]

公司介绍 - Carisma Therapeutics Inc.（Nasdaq: CARM）是一家专注于发现和开发创新免疫疗法的临床阶段生物制药公司[1] 参加会议 - 公司将在2024年4月5日至10日在加利福尼亚州圣迭戈举行的美国癌症研究协会（AACR）年会上进行演示[2] 展示内容 - Carisma将展示其专有的Engineered Microenvironment Converters（EM-C）平台的预临床数据[2] - Carisma将展示关于“Macrophages Expressing Synthetic Cytokine Receptors Reverse IL10-Mediated Immunosuppression within Solid Tumors and Promote Adaptive Immunity”的海报[3] 演讲内容 - 公司的首席科学官Michael Klichinsky将在主题为“Engineering Strategies Based on NK, gd T Cells and Their Receptors, and Macrophages”的专题研讨会上发表演讲[2]

PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6th at 2:50 pm ET. An audio webcast of the event will be available on the Company's Investor Events section of the Investor Re ...